The World Harmony Genetics Science and Technology Innovation Board IPO has been accepted for review, with a proposed fundraising of 1.7 billion yuan.

On June 29th, Nanjing Shewu Genomics Biotechnology Co., Ltd. (referred to as Shewu Genomics) has submitted its application for listing on the STAR Market of the Shanghai Stock Exchange. Huatai United Securities is its sponsoring institution, with plans to raise 1.7 billion yuan. The prospectus shows that Shewu Genomics is dedicated to the clinical application of high-throughput gene sequencing technology, mainly focusing on gene testing for cancer patients. Their services include guiding clinical drug selection based on specific gene types, predicting drug resistance mechanisms, monitoring post-operative recurrence, and exploring early screening and diagnosis for high-risk populations. The company provides molecular diagnostic services and products for precision oncology. The company has independently developed the ATG-seq ultra-sensitive ctDNA liquid biopsy technology, efficient targeted enrichment and probe capture technology, Mercury multi-omics early screening technology for tumors, Targeted RNA detection technology, and an AI multi-omics bioinformatics analysis platform. They are driving the transformation and application of cutting-edge technologies in the field of precision oncology, with over a million samples tested. In recent years, the company has actively expanded their product range and developed standardized reagent kits to broaden their business scope and customer base, nurturing new profit growth points. As of the end of the reporting period, the company has had 4 approved products on the market and 9 core pipelines in research and development, making it the only company in China's gene testing industry to be selected four times for the Innovative Medical Management Device Special Review Program. During the reporting period, the company's main business segments include clinical testing services, testing product sales, research and development services, and instrument equipment trading. Clinical testing services and testing product sales account for a large proportion of the main operating income, which is the main source of the company's revenue. In terms of sales, the company primarily uses a "direct sales with auxiliary distributors" model, with customers including medical institutions, pharmaceutical companies, research institutions, and cancer patients. According to Frost & Sullivan data, in the landscape of China's tumor high-throughput gene testing market, Shewu Genomics has a market share of approximately 10% in 2025, ranking at the forefront of the industry. Financially, in the years 2023, 2024, and 2025, the company's operating income is expected to be approximately 572 million yuan, 496 million yuan, and 577 million yuan respectively, with net profits of approximately 31.17 million yuan, 60.04 million yuan, and 81.60 million yuan.